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Abstract
5-Fluorouracil (5-FU) is a cytostatic drug associated with chemotherapy-induced cognitive impairments that many cancer
patients experience after treatment. Previous work in rodents has shown that 5-FU reduces hippocampal cell proliferation, a
possible mechanism for the observed cognitive impairment, and that both effects can be reversed by co-administration of
the antidepressant, fluoxetine. In the present study we investigate the optimum time for administration of fluoxetine to
reverse or prevent the cognitive and cellular effects of 5-FU. Male Lister-hooded rats received 5 injections of 5-FU (25 mg/
kg, i.p.) over 2 weeks. Some rats were co-administered with fluoxetine (10 mg/kg/day, in drinking water) for 3 weeks before
and during (preventative) or after (recovery) 5-FU treatment or both time periods (throughout). Spatial memory was tested
using the novel location recognition (NLR) test and proliferation and survival of hippocampal cells was quantified using
immunohistochemistry. 5-FU-treated rats showed cognitive impairment in the NLR task and a reduction in cell proliferation
and survival in the subgranular zone of the dentate gyrus, compared to saline treated controls. These impairments were still
seen for rats administered fluoxetine after 5-FU treatment, but were not present when fluoxetine was administered both
before and during 5-FU treatment. The results demonstrate that fluoxetine is able to prevent but not reverse the cognitive
and cellular effects of 5-FU. This provides information on the mechanism by which fluoxetine acts to protect against 5-FU
and indicates when it would be beneficial to administer the antidepressant to cancer patients.
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Introduction
Adjuvant chemotherapy is commonly used to treat patients with
breast cancer; however it is associated with many unwanted side
effects. One such effect is cognitive impairment, which can
encompass lack of concentration, problems with memory
formation and general confusion [1] and has been reported to
last for up to several years after completion of chemotherapy
treatment [2,3]. With the increasing survival of cancer sufferers, it
is becoming important to understand the causes of chemotherapy
induced cognitive impairment and to find ways to prevent it and
improve patient quality of life.
The antimetabolite, 5-fluorouracil (5-FU), is commonly used in
combination with other agents to treat cancer and has been
associated with cognitive impairment in patients [4,5]. Its ability to
cross the blood-brain barrier by passive diffusion enables it to
affect the brain when given systemically [6]. A small number of
studies, performed in rodents, have previously examined the effects
of 5-FU, with the majority finding that the drug impaired
cognition and suppressed hippocampal cell proliferation [6].
Consequently, the cytotoxic effect of chemotherapy on the
proliferation of neural stem and precursor cells required for adult
hippocampal neurogenesis has been considered as a possible
mechanism for chemotherapy-induced cognitive impairment
[7,8,9,10]. The subgranular zone of the dentate gyrus is one of a
limited number of regions where neurogenesis persists throughout
adulthood [11]. Memory formation and spatial memory are both
functions of the hippocampus and the proliferation and integration
of the neuronal precursors into existing circuits is thought to play a
functional role in this process [12,13].
Fluoxetine, a selective serotonin reuptake inhibitor (SSRI)
antidepressant, has been shown to increase cell proliferation in
the hippocampus in both rodents [14,15] and humans [16] and
improve memory in patients with impaired cognition [17,18,19].
Furthermore, recent rodent investigations in our group showed
that fluoxetine can reverse the impaired spatial memory and
reduced proliferation of hippocampal cells caused by treatment
with 5-FU [7] and methotrexate [10] chemotherapy.
In the present study, we utilised a rat model to confirm that co-
administration of fluoxetine during 5-FU treatment counteracts
the cognitive deficits and the reduction in proliferation and
survival of cells found in the subgranular zone caused by the
chemotherapy. The novel location recognition (NLR) task was
used to assess spatial working memory after 5-FU and fluoxetine
treatment. Cells which were proliferating in the dentate gyrus at
the end of the experiment were quantified by Ki67, a protein
expressed in all stages of the cell cycle [20]. To investigate the
effect of 5-FU and fluoxetine on the survival of newly generated
cells in the SGZ, Bromodeoxyuridine (BrdU) was injected over the
3 days immediately before 5-FU treatment. The number of
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30010surviving cells, marked at this time, was quantified at the end of
the experiment.
To understand whether the mode of action of fluoxetine
prevents or recovers the cognitive decline and reduced neurogen-
esis caused by 5-FU, fluoxetine was given for 3 different time
periods; before and during (preventative), after (recovery), and for
both of these periods combined (throughout), the 5-FU treatment
period (Fig. 1). These studies have demonstrated for the first time
that the action of the antidepressant fluoxetine, in chemotherapy
treatment, prevents the 5-FU induced cognitive deficits and
cellular changes but has little effect in recovery.
Materials and Methods
Ethics statement
Principles of laboratory animal care in this study were in
accordance to UK Home Office Guidance regulations, within the
‘‘moderate’’ severity band, with approval from the University of
Nottingham ethical committee board under permit number 40/
3283. Throughout the experiment, discomfort to animals was kept
to an absolute minimum. Animals remained in good health
throughout the study and never dropped more than 10% of their
highest body weight.
Animals and treatment
Male Lister-hooded rats (175–200 g; Charles River, UK) were
randomly allocated to vehicle, 5-FU, fluoxetine, 5-FU+fluoxetine
(throughout), 5-FU+fluoxetine (preventative) or 5-FU+fluoxetine
(recovery) groups (each, n=12). Animals were housed in cages of
four and allowed to habituate for 1 week prior to drug administration.
Rats were administered 5-FU (25 mg/kg, 5 i.p. doses, each 3
days apart, at a volume of 2.5 ml/kg, dissolved in 0.9% sterile
saline; Medac, Germany) or 0.9% sterile saline at an equivocal
volume. Fluoxetine treated animals initially had a lower fluid
intake than controls, probably due to a temporary taste aversion to
fluoxetine [21]. However, by the end of the experiment, all groups
had the same fluid intake. 3 BrdU injections were administered to
all groups, 24 h apart starting 2 days prior to their first 5-FU/
saline injection (100 mg/kg, i.p., at a volume of 4 ml/kg; Sigma
Aldrich, UK). This method of administration was selected for
maximum incorporation of BrdU into the nuclei of the cells [22].
Mean water consumption and mean animal weights per cage
were determined every 3 days to estimate a dose of 10 mg/kg/day
of fluoxetine (Pinewood Healthcare, Ireland, oral solution)
administered in the drinking water, for fluoxetine treated groups
of rats [10]. This mode of drug administration was seen to be
advantageous as it avoided the possible stress of isolation rearing,
administration by gavage or repeated injection and has been used
by a number of groups [23,24,25]. In addition, clinical reports
have suggested that studies of chemotherapy induced cognitive
impairment in patients can be confounded by stress [26].
Thompson et al. have shown that rats treated with fluoxetine in
drinking water for 37 days have fluoxetine and norfluoxetine
serum levels of 281644 and 12096123 nmol/l respectively [27],
levels comparable to levels achieved by injection [28]. The period
of administration for fluoxetine was at least 20 days which is
sufficient to have anxiolytic effects [29] and increase hippocampal
neurogenesis [15] in rats. Behavioural testing was carried out a
week after termination of fluoxetine treatment, as fluoxetine and
its primary metabolite norfluoxetine have a long half life and take
3 days to wash out of the system [28].
Drinking water treated with fluoxetine was administered to the
5-FU+fluoxetine (preventative) group starting 5 days before the
first BrdU injection and to the 5-FU+fluoxetine (recovery) group
starting the day of the last 5-FU/saline injection, both adminis-
trations were for 20 days. The fluoxetine and the 5-FU+fluoxetine
(throughout) groups received fluoxetine for the whole period of the
experiment, a total of 40 days (Fig. 1).
Throughout the experiment, rats were maintained under a 12 h
light/dark cycle (7.00/19.00h), food and water was provided ad
libitum and weighed every 3 days or daily during 5-FU
administration. Fluoxetine dose was calculated from mean animal
weight and fluid consumption per cage. All procedures were in
accordance to UK Home Office Guidance regulations and with
local ethical committee approval.
Behavioural testing
Novel location recognition (NLR). The NLR two-trial
spatial memory task is a spatial variant of a two trial object
recognition task adapted from Dix and Aggleton [30]. It was
carried out 1 week after fluoxetine treatment ended, as described
by Lyons et al [10]. In brief, rats were habituated to an arena (49
width666 length640 height cm) for 30 min, 24 h prior to testing
(during which their mean velocity was measured using EthoVision
4.1) and again for 3 min, 5 min before the familiarisation trial. In
the 3 min familiarisation trial, rats were placed in the arena to
explore two identical objects (weighted water bottles) in different
locations. Rats were removed for a 15 min retention period and
then reintroduced to the arena for the 3 min choice trial in which
Figure 1. Time line showing protocol of drug administration and behavioural testing. Arrows represent single i.p. injections of BrdU (fine)
and 5-FU/saline (thick). Brackets represent the period of time for which fluoxetine was administered in the drinking water. The day after Novel
location recognition (NLR) behavioural testing, animals were killed and their brains were removed.
doi:10.1371/journal.pone.0030010.g001
Effects of 5-FU and Fluoxetine in Rat
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time of both objects in both trials was recorded blind three times
and averaged using a stopwatch from digitised recordings.
Experiments were conducted at an illumination of 80 Lux
between 9.00 and 14.00 h.
Brain tissue preparation. Rats were killed by rapid
stunning and cervical dislocation the day after behavioural
testing. Brains were removed, cut sagittally and cryopreserved in
30% sucrose solution for three hours at 4uC, then submerged in
OCT-compound (VWR International Ltd, UK) and snap frozen
in liquid nitrogen-cooled isopentane. Brains were stored at 280uC
until being sectioned along the coronal plane using a Leica CM
100 cryostat (Leica Microsystems, UK) at 20 mm thickness at
220uC. The sections were thaw mounted onto 3-amino-
propylmethoxysaline (APES)-coated slides and stored at 220uC
until used for immunohistochemistry.
Immunohistochemistry. For immunostaining a systematic
random sampling technique was used [31]. Every 20
th section
throughout the entire length of the dentate gyrus was selected,
resulting in a total of 9–11 sections per brain. All immuno-
histochemistry incubations were carried out at room temperature
in a light-proof humidity chamber.
Ki67 and BrdU staining was carried out as described by Lyons
et al. [10]. Briefly, sections were incubated with monoclonal
mouse Ki67 primary antibody (1:300; Vector laboratories, UK) for
1 h, followed by 1 h incubation with Alexa 555 donkey anti-mouse
(1:300; Invitrogen, UK) or with polyclonal sheep BrdU primary
antibody (1:100; Abcam, UK) for 16–20 h followed by Alexa 488
donkey anti-sheep secondary antibody (1:300; Invitrogen, UK) in
PBS. Sections were mounted with (diamidinophenylindole) DAPI
(1.5 mg/ml) nuclear marker (Vector laboratories, UK) and
coverslipped.
Figure 2. Body weights of rats (a) and their fluid intake (b) during fluoxetine treatment period (mean ± SEM). Arrows indicate 5-FU
(20 mg/kg)/saline injections. Fluoxetine was given in drinking water (10 mg/kg/day) from day 1 to day 20 for the 5-FU+fluoxetine (preventative)
group, from day 21 to day 40 for the 5-FU+fluoxetine (recovery) group and from day 0 to day 40 for the 5-FU+fluoxetine (throughout) and the
fluoxetine alone groups.
doi:10.1371/journal.pone.0030010.g002
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3 fluorescence microscope. BrdU and Ki67 positive cells which co-
localised with the DAPI nuclear staining within the subgranular
zone of both hippocampal blades were counted. By combining cell
counts per section for the whole dentate gyrus and multiplying by
20, an estimate of total immuno positive cell numbers was
produced [32]. All counting was performed blind.
Statistical analysis. Student’s paired t tests were used to
compare exploration times of animals in the familiarisation and
choice trials. Preference indices (PI) were created by expressing
time spent exploring the object in the novel location as a
percentage of the sum of exploration time of novel and familiar
locations in the choice trial, to create a single value to compare
between groups [33]. PI was compared to 50% chance using a
one-sample t test. Two-way repeated measured ANOVA was run
to determine difference in animal weight and fluid intake between
treatment groups. One-way ANOVA was used to compare total
exploration time and average velocity of the animals and cells
counts. When ANOVA was significant it was followed by
Bonferroni post-hoc test. Statistical analysis and graphs were
created using GraphPad Prism 5 and significance was regarded as
p,0.05.
Results
5-FU and fluoxetine reduce weight gain and fluid intake
Both treatment and time had a significant effect on body weight
(F5,1848=11.50, F28,1848=2040, p,0.001 respectively, two-way
repeated measures ANOVA, Fig. 2a). Both 5-FU and fluoxetine
significantly reduced weight gain which is attributed to disruption
of intestinal absorption by 5-FU [34] and fluoxetine [35].
Treatment and time significantly affected the amount of water
drunk (F5,169=17.93, F14,168=52.09, p,0.001 respectively, two
-way repeated measures ANOVA, Fig. 2b). However, by the end
Figure 3. Mean exploration times (mean ± SEM) of the rats for each object in the familiarisation (a) and choice (b) trials. There was no
significant difference in exploration time of either object for any group in the familiarisation trial (p.0.05). In the choice trial, all groups spent
significantly longer exploring the object in the novel location (*p,0.05, **p,0.01), except the groups receiving 5-FU alone or 5-FU with fluoxetine in
recovery (p.0.05). Preference indices (PI, (c), mean 6 SEM) were created by expressing time spent exploring the object in the novel location as a
percentage of the sum of exploration time of novel and familiar locations in the choice trial (Bruel-Jungerman et al. 2005). All groups were
significantly different from chance (*p,0.05, **p,0.01, ***p,0.001), other than the groups receiving 5-FU alone or 5-FU with fluoxetine in recovery
(p.0.05). The total exploration time (mean 6 SEM) for both trial combined (d) did not differ significantly between groups (p.0.05).
doi:10.1371/journal.pone.0030010.g003
Effects of 5-FU and Fluoxetine in Rat
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way ANOVA). Although, the fluid intake fell per kg as animals
increase in weight, the actual fluid intake did not drop per animal
(data not shown).
Fluoxetine reverses the behavioural deficits caused by 5-
FU when administered in prevention but not recovery
The NLR test makes use of the preference of rats for novelty to
measure the ability of rats to discriminate between objects in novel
and familiar locations. In the familiarisation trial, the rats explored
2 identical objects and no group showed a significant difference in
exploration time for either object (p.0.05, Fig. 3a) indicating no
preference for either object’s location. During the choice trial
(Fig. 3b) however, the groups of vehicle treated rats, rats receiving
only fluoxetine and rats receiving both 5-FU and fluoxetine
throughout or for prevention were able to perform the memory
task, spending significantly longer exploring the object in the novel
location compared to the object in the familiar location (all
p,0.05). In contrast, rats treated with 5-FU only or 5-FU with
fluoxetine in recovery showed no object preference, and no
significant difference in exploration time for either object (p.0.05),
indicating an impairment in memory. Conversion of raw
exploration times showed that the means of the PI of these 2
groups did not differ from a level of 50% chance, whereas the
mean PI of the other groups was significantly different (Fig. 3c).
No significant difference was found between groups for either
totalexplorationtime(Fig.3d)forbothtrialsormeanvelocity(Fig.4)
indicating none of the groups were impaired in their activity.
Fluoxetine abolishes the reduction in cell proliferation in
the dentate gyrus caused by 5-FU when administered in
prevention but not recovery
Cell proliferation in the subgranular zone at the end of the
experiment (30 days after the final saline/5-FU injection) was
quantified using Ki67 (Fig. 5a, b, c, d). Rats receiving only 5-FU
had a significantly lower number of Ki67-positive cells and rats
receiving only fluoxetine had a significantly larger number
compared to vehicle-treated controls. The number of Ki67-
positive cells in rats treated with both 5-FU and fluoxetine did not
significantly differ from the controls when fluoxetine was
administered throughout; in prevention and in recovery. However
rats administered fluoxetine in recovery had the lowest numbers of
Ki-67 positive cells. These results indicate that 5-FU has a long
term effect, reducing cell proliferation in the subgranular zone for
at least four weeks. This effect can be counteracted by fluoxetine if
it is administered before and during the 5-FU treatment period,
but only incompletely counteracted if fluoxetine is administered
after chemotherapy treatment.
Fluoxetine prevents the reduction in cell survival caused
by 5-FU when administered during but not after
chemotherapy
A course of 3 BrdU injections was given to animals preceding 5-
FU or saline injection to label cells dividing at the start of 5-FU
treatment. BrdU-positive cells were counted in the dentate gyrus
and SGZ at the end of the experiment to quantify the survival of
these cells (Fig. 6a, b, c, d). There were significantly more BrdU-
positive cells in rats treated with fluoxetine only compared with the
control group and significantly fewer positive cells in rats treated
with 5-FU. The rats treated with both 5-FU and fluoxetine did not
have a significantly different number of BrdU-positive cells than
the controls when fluoxetine was administered throughout and in
prevention, but when fluoxetine was only administered in
recovery, the rats had a significantly smaller number. These
results suggest that when administered before and during, but not
after 5-FU treatment, fluoxetine can protect neural precursors
from cell loss induced by 5-FU.
Discussion
The present study showed that the chemotherapy agent 5-FU
caused a memory impairment which was associated with a
reduction in both the proliferation and survival of neural
precursors in the subgranular zone of the dentate gyrus. These
effects were counteracted when the SSRI antidepressant fluoxetine
was co-administered before and during (preventative) but not after
(recovery) 5-FU treatment.
The NLR test was chosen as a test of spatial memory as it is
hippocampal dependent [36] and relies on the animals’ sponta-
neous preference for novelty, and does not require positive or
negative reinforcers. In the present study, 5-FU-treated animals
were unable to recognise an object in a novel as opposed to a
familiar location, suggesting a memory deficit in contrast to saline
treated controls. This is in line with patient reports of
chemotherapy-induced cognitive impairments. Fluoxetine has
been previously shown to have cognitive benefits for rats treated
with chemotherapy when given before during and after chemo-
therapy treatment [10]. This positive effect remained when
fluoxetine was given before and during the 5-FU treatment but
was not found when fluoxetine administration started after the
final 5-FU injection, indicating that fluoxetine can protect from
the effects of chemotherapy but cannot compensate after
chemotherapy has been given.
Disruption of neurogenesis is a possible mechanism by which 5-
FU causes cognitive impairment [7,8]. Production and survival of
new neurones in the hippocampus is thought to be essential for
spatial memory and learning [12,13] and cognitive impairments
are seen when neurogenesis is disrupted by irradiation [37,38],
chemotherapy drugs [7,10,39] or genetic manipulation [40]. In
the present study the effects of 5-FU and fluoxetine on production
and survival of new hippocampal cells were examined. 5-FU
Figure 4. Mean velocity (mean ± SEM) of rats recorded during
the habituation period using EthoVision 4.1. No significant
difference (p.0.05) was found between each group.
doi:10.1371/journal.pone.0030010.g004
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Bar scales indicate 20 mm. Total numbers of BrdU-positive cells (mean 6 SEM) in the dentate gyrus were estimated from cell counts (d). Rats receiving
5-FU had significantly fewer BrdU-positive cells (p,0.001) in the SGZ and rats receiving fluoxetine had significantly more (p,0.01) than the saline-
treated control group. Treatment groups receiving both 5-FU and fluoxetine throughout and in prevention did not significantly differ from the
controls (p.0.05). The group receiving 5-FU with fluoxetine only in recovery had significantly fewer BrdU-postive cells than the control group
(p,0.001).
doi:10.1371/journal.pone.0030010.g006
Figure 5. Photographs of the nuclei of cells in the SGZ of the dentate gyrus (blue, a), Ki67-positive cells (red, b) and the photos
merged (c). Bar scales indicate 20 mm. Total numbers of Ki67-positive cells (mean 6 SEM) in the dentate gyrus were estimated from cell counts (d).
Rats receiving 5-FU had significantly fewer Ki67-positive cells (p,0.01) in the subgranular zone (SGZ) and rats receiving fluoxetine had significantly
more (p,0.05) than the saline-treated control group. The other treatment groups receiving both 5-FU and fluoxetine did not significantly differ from
the controls (p.0.05).
doi:10.1371/journal.pone.0030010.g005
Effects of 5-FU and Fluoxetine in Rat
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BrdU labelled at the start of 5-FU treatment (Fig. 6). In addition
quantification of cell division (Ki-67 positive cells) at the end of the
experiment, 30 days after completion of 5-FU treatment, showed
that cell proliferation was significantly less than controls (Fig. 5).
The effect of fluoxetine on animals not receiving chemotherapy
was to increase cell survival and cell proliferation (Fig. 5; 6) as
previously reported [10]. Fluoxetine given either only during 5-FU
treatment (preventative) or throughout the whole experiment
(throughout) showed no reduction in cell proliferation or cell
survival at the end of the experiment. Animals administered
fluoxetine for 20 days after the end of 5-FU treatment, showed the
same reduction in cell survival as the chemotherapy only group
indicating that loss of cells which were dividing at the start of 5-FU
treatment, occurred during chemotherapy treatment and was not
affected by subsequent fluoxetine treatment. The level of cell
proliferation in this group, at the end of the experiment, was not
significantly different from controls but lay between the values
found in control and 5-FU only treated groups (Fig. 5). This may
indicate some recovery in cell proliferation with fluoxetine
administration after 5-FU treatment.
The results in the present study are the first to examine the time
course of the effects of fluoxetine on the response to the
chemotherapy agent, 5-FU, and are consistent with the earlier
work from our group [7,8] as well as other studies which show that
5-FU affects memory immediately (2 days) [41] and for at least 5
weeks [42] after drug administration as well as a reduction in cell
proliferation in the SGZ [7,8]. The proliferation, survival and
apoptosis of neural progenitors are all involved in memory
formation and the stage of growth of newly-born neurones when
learning and memory takes place is an important factor [40]. In
the present study, memory was affected 4 weeks after 5-FU
chemotherapy treatment indicating that 5-FU had a long lasting
effect. We show here that fluoxetine increases the survival of cells
by protecting newly forming neurones from 5-FU.
Fluoxetine may be acting by increasing the level of brain-
derived neurotrophic factor (BDNF) [43,44] [45] and indirectly
affecting neurogenesis or by directly increasing the proliferation of
hippocampal neural stem cells [46]. Several recent reports have
shown that fluoxetine itself has anti cancer properties [47,48,49]
and can potentiate the action of some chemotherapy agents [50].
Further work will be needed to establish the actions of fluoxetine
on different cancers and its interaction with chemotherapy agents
in particular as fluoxetine can inhibit the cytochrome P450
enzymes involved in drug metabolism [51].
The results of the present study show that fluoxetine can protect
newly born hippocampal neurones from the cytotoxic effects of 5-
FU. If similar effects in preventing chemotherapy-induced memory
deficits are found in patients, these results may offer a relatively
simple way to counteract cognitive impairment in this situation.
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